News

Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant in Houston, part of a larger $40 billion U.S. investment pledge. On the very same day, British regulators cleared Eli Lilly and Company (NYSE:LLY)’s […]

Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.

What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.

Shares recently traded at $1,280 each, so a split wouldn't be surprising.

Apple paid Ireland $17bn in taxes last year, representing 40 per cent of its worldwide total, according to filings that offer new insight into...

The home to some large pharma companies and many smaller biotechs, have risen over 6% this week. The main catalyst was that Moderna and Merck announced successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence. “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.

Eli Lilly stock broke out of a flat base and reached a record high. Its Mounjaro drug sales surged 91% in the second quarter.

Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.

Can anyone challenge Eli Lilly in the weight loss space?

Investors took profits after record highs, but Mounjaro and Zepbound continue producing extraordinary growth.

Eli Lilly (LLY) is back in focus after the UK's Medicines and Healthcare products Regulatory Agency approved Foundayo, a once daily oral GLP-1 drug for weight management and type 2 diabetes. See our latest analysis for Eli Lilly. The Foundayo approval arrives during a strong run for Eli Lilly’s stock, with a 30 day share price return of 11.63% and a year to date share price return of 18.51%. Over the longer term, total shareholder returns of 82.64% over one year and 136.19% over three years...

The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.

The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.

NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.

Dow Jones futures: Crude oil continues to climb while bitcoin jumped again amid a weak dollar. Walmart earnings are in focus.

CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.

You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.

Wolfe Research identified seven stocks combining strong earnings, rapid sales growth, and positive momentum in a tough market.

The battle between Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) has so far been defined by blockbuster injectable weight loss drugs. But the next phase of that rivalry may look very different. Instead of competing over weekly injections, both companies are now racing to establish themselves in what could become the next major opportunity in […]

These two stocks both have market caps of more than $1 trillion, but Eli Lilly's valuation is supported by strong financials.

The S&P 500 and Nasdaq rose slightly Wednesday as Treasury yields fell. Moderna and Merck fueled big gains for biotechs, drugmakers.

Eli Lilly stock is riding obesity-drug growth, rising revenue and retatrutide hype. See the latest LLY price prediction through 2027.

The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.

AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.

Novo Nordisk stock has fallen sharply over the past three years, yet the broader valuation checks still flag it as looking cheap rather than stretched. Recent headlines around obesity treatments, intellectual property protection and a large buyback programme add extra context to whether that discount is justified. The share price has declined 49.9% over the past three years, which suggests many investors have already reset their expectations for the stock. Growth expectations around GLP-1...

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

Lilly, Novo, and Merck have each priced in a radically different version of the next two years, and one of them looks like a setup where the market has it badly wrong.

Eli Lilly's GLP-1 portfolio outpaces its rival in Q2, while Foundayo gains momentum and can challenge Wegovy's early oral obesity lead.

PFE aims to break into the obesity market with berobenatide, a potential monthly treatment designed to compete with leading GLP-1 therapies.

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.